ArticleChinese medicine2026
Pharmacokinetics and homeostatic impact of golden bile powder: evidence from surrogate analyte-based UPLC-MS/MS in rats.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGolden bile powder (GBP), an artificial bear bile powder, is used for liver protection and contains taurine-conjugated bile acids (BAs) with broad pharmacological activities. However, its pharmacokinetics and effects on endogenous BA homeostasis are unclear.
methodsSprague-Dawley rats received oral administration of GBP (54 mg/kg/day) combined with three deuterated taurine-conjugated BAs at fixed ratios for 7 days to facilitate separate analysis of changes in exogenous and endogenous BAs following administration. Single deuterated taurine-conjugated BA groups were also included. Blood samples were collected over a 24 h time window on days 1 and 7. We developed and validated a surrogate analyte-based UPLC-MS/MS method to quantify six BAs in rat plasma, eliminating endogenous interference. Pharmacokinetic parameters were obtained by non-compartmental analysis, and gender differences and accumulation effects were assessed using appropriate statistical comparisons.
resultsThe UPLC-MS/MS method demonstrated good linearity (r > 0.999), accuracy (89.1%-115%), precision (RSD < 15%), and stability (within ± 15%). Pharmacokinetic studies showed taurine-conjugated BAs in GBP had long half-lives (8.43-12.7 h) and gender-specific accumulation, with females displaying higher systemic exposure. For example, the AUC
conclusionsThis work establishes an analytical framework for evaluating endogenous and exogenous BA dynamics, contributing to future mechanistic and translational studies involving GBP and its potential applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.